industry icon

Crestor - Astrazeneca

Study ID: 239
Research Type: Validity
Expiration Date: 2009-03-31
Crestor is the brand name drug sold by AstraZeneca of the drug rosuvastatin calcium. It is a lipid-lowering agent for oral administration.
Completed 2009-03-31
Reward $50,000

The patent in this study is a reissue of US 5,260,444. The reissue application was filed on August 27, 1998, more than 2 years after the ‘444 Patent issued. A reissue patent application filed more than 2 years after issuance can only seek to narrow the claims of the original patent. The only claims allowed in the reissue application were claims 6, 7 and 8. Therefore Re37,314 only covers the specific compound of claim 6 and the sodium or calcium salts thereof.

During the prosecution of the reissue application, the applicant successfully argued that the chemical composition shown in claim 6 was not anticipated or obvious. A copy of the imaged filewrapper is available on the USPTO website. You can access the filewrapper by using the PAIR function at the USPTO site.

The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt.

Study Patents
Study Downloads
Research Requirements
Latest Date for Responses
Relevant Patent Dates
US Patent Date
Priority Date
US Application Date
Priority Date
EP Date
Publication Date
Other Patent Authorities
Publication Date
See the claims in the downloadable copies of the patent.
Get Started

Become a Researcher
To date, Article One has paid out $6,777,032 to the Researchers.

Choose your work
Select research projects that suit your personal preferences.

Earn Rewards
Receive monetary compensation for submitting high-quality research.

Learn while you earn
Explore new tech areas as you develop your research skills.

Feel free to ask us to learn more about getting started as a Researcher.